Cholecystokinin 1 receptor activation restores normal mTORC1 signaling and is protective to Purkinje cells of SCA mice-Reference-Cited by-同舟云学术

Cholecystokinin 1 receptor activation restores normal mTORC1 signaling and is protective to Purkinje cells of SCA mice

Published:2021-10 Issue:2 Volume:37 Page:109831
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Wozniak Emily A.L.,Chen Zhao,Paul Sharan,Yang Praseuth^ORCID,Figueroa Karla P.,Friedrich Jill,Tschumperlin Tyler,Berken Michael^ORCID,Ingram Melissa,Henzler Christine^ORCID,Pulst Stefan M.,Orr Harry T.

Funder

National Institutes of Health

National Institute of Neurological Disorders and Stroke

University of Minnesota Twin Cities

The University of Utah

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference38 articles.

1. mTORC1 and mTORC2 have largely distinct functions in Purkinje cells;Angliker;Eur. J. Neurosci.,2015

2. Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide;Asin;Am. J. Physiol.,1992

3. A-71623, a selective CCK-A receptor agonist, suppresses food intake in the mouse, dog, and monkey;Asin;Pharmacol. Biochem. Behav.,1992

4. Trimmomatic: a flexible trimmer for Illumina sequence data;Bolger;Bioinformatics,2014

5. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat;Burright;Cell,1995

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebellar Heterogeneity and Selective vulnerability in Spinocerebellar Ataxia Type 1 (SCA1);Neurobiology of Disease;2024-07

2. Transcriptional modulation unique to vulnerable motor neurons predicts ALS across species and SOD1 mutations;2024-03-17

3. Different Purkinje cell pathologies cause specific patterns of progressive gait ataxia in mice;Neurobiology of Disease;2024-03

4. A multi-faceted approach to unravel coding and non-coding gene fusions and target chimeric proteins in ataxia;Journal of Biomolecular Structure and Dynamics;2024-02-27

5. Advances in cerebellar disorders: pre-clinical models, therapeutic targets, and challenges;Expert Opinion on Therapeutic Targets;2023-10-03